🔹 Dr. Arnaud Bayle discussed the patient voice at the Policy mini oral session at @myesmo. #ESMO25 #ESMO @ArBayle

Great talk by ⁦@BenjaminBesseMD⁩ on de-escalation strategies in oncology. Young fellow, if you missed it, check it on the #ELCC25 platform. We should change our mind and aim to de-escalade whenever possible.

[Concours 📷] Mobilisons-nous pour la journée mondiale du cancer du poumon le 1er aout . À tous les patients, partagez une photo de vous en vacances avec le tag #EspoirCapturé sur Instagram ou envoyez votre photo à: Concourphoto1eraout@alkfrancecancerpoumon.com

📻 Lutte contre le #cancer : une startup propose de trouver les essais cliniques les plus prometteurs. En quelques clics seulement, les patients trouvent l’essai clinique le plus proche de chez eux avec @klineo_fr. À écouter sur @franceinter 👇 https://t.co/HYJyZXYDN8

[LYSA Days] Presentation by Valentin Moine from LYSARC about @klineo_fr #LYSATours24 @ArBayle @nDrizard @TPeyresblanques

Confidence intervals for expected survival probabilities obtained from neural networks - happy to see this paper out of joint PhD student with MICS @centralesupelec and Oncostat @Cesp_Inserm @GustaveRoussy @UnivParisSaclay https://t.co/f55Wzh8JzG

Visionary viewpoint in @TheLancet from @GustaveRoussy colleagues with huge potential public health impact ! @FAndreMD @BenjaminBesseMD AlexandraLeary

Great Pdh work by Valentine Grumberg supervised by Prof Borget on estimating clinical benefit of immunotherapies in advanced cancers in France in 2014-21 @Cesp_Inserm #Oncostat @GustaveRoussy

🌟 Exciting discussions on the future of #precisionmedicine ! 🌍Thrilled to join amazing colleagues -The Paris Connection- @ArBayle & @euapmbrussels the terrific Denis Horgan to discuss the vision for precision medicine access for all and clinical trial access for everyone!

Looking for inputs from my public health friends @darioT_ @LuisCB_MedPharm @FroitbergM @Raffa_Casolino !

Passionate discussions on access/public policy issues from the US and EU perspective with @VivekSubbiah @euapmbrussels before #ESMO2023 @myESMO @ASCO

Perception of cancer by pts is based on organ-of-origin without mechanistic consideration. @AliceFranzoi et al explain why cancer representations should evolve toward comprehensive portraits that include biology. This is a task of the IHU @PrismCenter https://t.co/5vBnffk6Oi

More from @AliceFranzoi and coll. on this topic in Annals of Oncology https://t.co/fGX2JpBlmu

Join @myESMO and let us know what's the status of #access to cancer meds in the 🌍🌎🌏 Your contribution is vital! 👇👇👇

An ESMO study revealed that advanced genetic testing, is largely inaccessible to #CancerPatients across Europe. ESMO can play a pivotal role to build a framework for #PrecisionMedicine that reaches all patients who can benefit from it. 📌 https://t.co/No59OkYSsm

@DanChaltiel @StefanMichiels

@RosGiuliani @oncology_bg @darioT_ @kjmeetswrld @peters_solange @DrYukselUrun @Raffa_Casolino @GustaveRoussy @uicc

Advanced genetic testing remains largely inaccessible to cancer patients across Europe... Thanks to all experts, national societies.. who made this study possible! Collaboration is key to moving forward on access to sequencing! @myESMO @BenjaminBesseMD https://t.co/UCArZji2CM

Results of a study performed by the @myESMO Global Policy Committee aimed at assessing the status of access to bimolecular technologies in 48 European countries are reported in Annals of Oncology 👇 https://t.co/Y2Tp4PJiCe @ArBayle @peters_solange @RosGiuliani 2/3

I am absolutely thrilled to have the opportunity to contribute as a peer reviewer of the data for this exceptional study, which also features the invaluable expertise of my esteemed mentor @DrYukselUrun in the assessment of genomic profiling in our country! @ArBayle @myESMO